经皮给药优于口服：用利斯的明治疗阿尔茨海默病患者的照料者满意度的观察性研究。
Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.
机构信息
Fundació ACE - Barcelona Alzheimer Treatment and Research Centre, Barcelona, Spain.
出版信息
Dement Geriatr Cogn Disord. 2013;35(1-2):23-33. doi: 10.1159/000345989. Epub 2013 Jan 9.
BACKGROUND AND AIMS
Poor adherence to anti-dementia drugs is common among patients with Alzheimer's disease. This study evaluated whether caregivers were more satisfied with, and patients more adherent to, transdermal rivastigmine than oral rivastigmine.
METHODS
Neurologists, psychiatrists and geriatricians collected sociodemographic and clinical data from 1,078 patients and administered the Treatment Satisfaction with Medicines (SATMED-Q) and the Morisky-Green questionnaires to their caregivers at outpatient consultations.
RESULTS
Satisfaction reported was greater with transdermal than oral rivastigmine: mean ± SD of the total SATMED-Q score, 72.5 ± 14.1 vs. 65.2 ± 12.5, p < 0.001. The proportion of adherent patients was greater with transdermal than with oral rivastigmine (65.0 vs. 41.4%, p < 0.001). Satisfaction, in turn, was significantly greater in adherent cases than in nonadherent cases.
CONCLUSIONS
Facilitating the administration of anti-dementia drugs would improve adherence.
背景和目的
阿尔茨海默病患者对抗痴呆药物的依从性较差较为常见。本研究评估了经皮利伐斯的明是否比口服利伐斯的明更能让护理人员满意，患者更能坚持服用。
方法
神经科医生、精神科医生和老年科医生在门诊就诊时从 1078 名患者那里收集了社会人口统计学和临床数据，并向他们的护理人员发放了治疗药物满意度问卷（SATMED-Q）和 Morisky-Green 问卷。
结果
与口服利伐斯的明相比，经皮利伐斯的明的满意度更高：总 SATMED-Q 评分的平均值 ± 标准差分别为 72.5 ± 14.1 和 65.2 ± 12.5，p < 0.001。与口服利伐斯的明相比，经皮利伐斯的明的依从性患者比例更高（65.0% vs. 41.4%，p < 0.001）。反过来，依从性患者的满意度显著高于非依从性患者。
结论
促进抗痴呆药物的使用将提高患者的依从性。
Zotero 插件